Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2022, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 15, 1, 36, 9 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 5 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Opium (Opioid) Addiction – Overview
Opium (Opioid) Addiction – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opium (Opioid) Addiction – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opium (Opioid) Addiction – Companies Involved in Therapeutics Development
Adial Pharmaceuticals Inc
Alar Pharmaceuticals Inc
Amygdala Neurosciences Inc
Ananda Scientific Inc
Antheia Inc
Aoxing Pharmaceutical Company Inc
Aphios Corp
Aquilus Pharmaceuticals Inc
Atai Life Sciences NV
Benuvia Therapeutics Inc
BioCorRx Inc
BioXcel Therapeutics Inc
Bridge Therapeutics Inc
Bright Minds Biosciences Inc
Camurus AB
Ceruvia Lifesciences LLC
Cessation Therapeutics LLC
Copernicus Therapeutics Inc
Creative Bio-Peptides Inc
Delpor Inc
DemeRx Inc
DMK Pharmaceuticals Inc
Elysium Therapeutics Inc
Emergent BioSolutions Inc
Ensysce Biosciences Inc
Eolas Therapeutics Inc
Epiodyne Inc
Ethismos Research Inc
Exxel Pharma Inc
Fab’entech SA
Fannin Partners LLC
Gilgamesh Pharmaceuticals Inc
Hunan Saiao Pharmaceutical Co Ltd
Indivior Plc
Inimmune Corp
Jazz Pharmaceuticals Plc
Kinoxis Therapeutics Pty Ltd
Lyndra Therapeutics Inc.
Mayne Pharma Group Ltd
Mebias Discovery LLC
Mind Medicine MindMed Inc
Nirsum Laboratories Inc
Omeros Corp
Opiant Pharmaceuticals Inc
Orexo AB
Orphomed Inc
Osmotica Pharmaceutical Corp
OYE Therapeutics Inc
Palisades Therapeutics
Phoenix PharmaLabs Inc
Plumb Pharmaceuticals LLC
Revive Therapeutics Ltd
SafeRX Pharmaceuticals Inc
Sen-Jam Pharmaceutical LLC
Senzer Ltd
Serina Therapeutics Inc
Sparian Biosciences Inc
Syntropharma Ltd
Titan Pharmaceuticals Inc
VDM Biochemicals Inc
Vivreon Biosciences LLC
Yichang Humanwell Pharmaceutical Co Ltd
Zynerba Pharmaceuticals Inc
Opium (Opioid) Addiction – Drug Profiles
(buprenorphine + naloxone) – Drug Profile
(buprenorphine + naloxone) – Drug Profile
(buprenorphine hydrochloride + naloxone hydrochloride) – Drug Profile
(cannabidiol + dronabinol) – Drug Profile
(disulfiram + methadone hydrochloride) IR – Drug Profile
(disulfiram + oxycodone hydrochloride) IR – Drug Profile
ALA-1300 – Drug Profile
amitifadine – Drug Profile
ANS-6637 – Drug Profile
Antibody for Drug Overdose, Opioid Addiction and Poisoning – Drug Profile
APH-1501 – Drug Profile
AQU-010 – Drug Profile
arbaclofen ER – Drug Profile
ATLX–0199 – Drug Profile
BICX-101 SR – Drug Profile
BICX-102 – Drug Profile
BMB-101 – Drug Profile
buprenorphine – Drug Profile
buprenorphine ER – Drug Profile
buprenorphine PR – Drug Profile
buprenorphine SR – Drug Profile
cannabidiol – Drug Profile
dexmedetomidine – Drug Profile
DPI-125 – Drug Profile
Drug to Inhibit PDE4 for Opioid Addiction – Drug Profile
EORA-101 – Drug Profile
Gene Therapy for Opioid use Disorder – Drug Profile
GM-1020 – Drug Profile
GM-300X – Drug Profile
hydrocodone IR – Drug Profile
ibogaine – Drug Profile
INDV-2000 – Drug Profile
Kapanol – Drug Profile
KNX-100 – Drug Profile
KUR-101 – Drug Profile
levomethadone ER – Drug Profile
LSP-29166 – Drug Profile
MEB-1170 – Drug Profile
Monoclonal Antibody for Opioid Use Disorder – Drug Profile
nalmefene – Drug Profile
nalmefene SR – Drug Profile
naltrexone – Drug Profile
naltrexone ER – Drug Profile
naltrexone hydrochloride – Drug Profile
naltrexone LA – Drug Profile
naltrexone SR – Drug Profile
Noribogaine – Drug Profile
NRS-033 – Drug Profile
NRS-067 – Drug Profile
NYPRG-101 – Drug Profile
OMS-405 – Drug Profile
OMS-527 – Drug Profile
Ondansetron hydrochloride – Drug Profile
Opioid Addiction – Drug Profile
Opioid Vaccine Program – Drug Profile
OPNT-006 – Drug Profile
ORP-106 – Drug Profile
OYE-001 – Drug Profile
PF-26810 ER – Drug Profile
PPL-103 – Drug Profile
psilocybin For Opium (Opioid) Addiction – Drug Profile
PT-150 – Drug Profile
RAP-103 – Drug Profile
SBS-226 – Drug Profile
SER-227 – Drug Profile
SJP-006 – Drug Profile
SJP-007 – Drug Profile
Small Molecule to Antagonize D3 Receptor for Opioid Addiction – Drug Profile
Small Molecules to Antagonize Mu Receptor for Opioid Use Disorder – Drug Profile
thienorphine hydrochloride – Drug Profile
URB-937 – Drug Profile
Vaccine 1 for Opioid Addiction – Drug Profile
Vaccine for Opioid Addiction – Drug Profile
Vaccine for Opioid Use Disorder – Drug Profile
Vaccine for Opium Addiction – Drug Profile
VDM-001 – Drug Profile
VV-7063 – Drug Profile
zolunicant hydrochloride – Drug Profile
Opium (Opioid) Addiction – Dormant Projects
Opium (Opioid) Addiction – Discontinued Products
Opium (Opioid) Addiction – Product Development Milestones
Featured News & Press Releases
Apr 28, 2022: Delpor announces first subjects dosed in phase 1 clinical trial of once or twice-yearly naltrexone implant for opioid addiction
Apr 27, 2022: BioCorRx begins recruitment for clinical trial of BICX104, an implantable naltrexone pellet for the treatment of opioid use disorder
Apr 11, 2022: BioCorRx announces additional award of nearly $100,000 from NIDA for BICX104, its implantable naltrexone pellet for the treatment of opioid use disorder
Mar 16, 2022: BioCorRx announces IRB approval to begin phase I clinical trial of BICX104, an implantable biodegradable Naltrexone Pellet for the treatment of opioid use disorder
Feb 14, 2022: BioCorRx announces Orange County Research Center as clinical trial site for first-in-human clinical trial of BICX104
Jan 24, 2022: Adial Pharmaceuticals receives notice of allowance on U.S. patent for the treatment for opioid use disorder using AD04
Jan 12, 2022: Alar announces significant progress on developing long-acting buprenorphine injectable ALA-1000
Jan 04, 2022: ANANDA Scientific announces FDA approval of the IND for the clinical trial on the treatment of Opioid Use Disorder (OUD)
Jan 04, 2022: MindMed successfully completes phase 1 clinical trial of 18-MC
Oct 19, 2021: ANANDA Scientific’s Liquid Structure cannabidiol (CBD) to be clinically evaluated for opioid use disorder
Oct 07, 2021: BioCorRx files patent application with the Russian Patent Office (Rospatent) for Naltrexone Implant
Sep 29, 2021: ANANDA Scientific and David Geffen School of Medicine UCLA announce clinical trial utilizing liquid structure cannabidiol (CBD) for the treatment of opioid use disorder (OUD)
Sep 22, 2021: BioCorRx files patent application with USPTO for Naltrexone implant
Sep 22, 2021: Bright Minds Biosciences provides scientific update
Sep 21, 2021: DemeRx doses first subject in phase 1/2a study of DMX-1002 (Ibogaine) in opioid use disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Opium (Opioid) Addiction, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Universities/Institutes, 2022
Table 6: Products under Development by Companies, 2022
Table 7: Products under Development by Companies, 2022 (Contd..1)
Table 8: Products under Development by Companies, 2022 (Contd..2)
Table 9: Products under Development by Companies, 2022 (Contd..3)
Table 10: Products under Development by Universities/Institutes, 2022
Table 11: Number of Products by Stage and Target, 2022
Table 12: Number of Products by Stage and Target, 2022 (Contd..1)
Table 13: Number of Products by Stage and Mechanism of Action, 2022
Table 14: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 15: Number of Products by Stage and Route of Administration, 2022
Table 16: Number of Products by Stage and Molecule Type, 2022
Table 17: Opium (Opioid) Addiction – Pipeline by Adial Pharmaceuticals Inc, 2022
Table 18: Opium (Opioid) Addiction – Pipeline by Alar Pharmaceuticals Inc, 2022
Table 19: Opium (Opioid) Addiction – Pipeline by Amygdala Neurosciences Inc, 2022
Table 20: Opium (Opioid) Addiction – Pipeline by Ananda Scientific Inc, 2022
Table 21: Opium (Opioid) Addiction – Pipeline by Antheia Inc, 2022
Table 22: Opium (Opioid) Addiction – Pipeline by Aoxing Pharmaceutical Company Inc, 2022
Table 23: Opium (Opioid) Addiction – Pipeline by Aphios Corp, 2022
Table 24: Opium (Opioid) Addiction – Pipeline by Aquilus Pharmaceuticals Inc, 2022
Table 25: Opium (Opioid) Addiction – Pipeline by Atai Life Sciences NV, 2022
Table 26: Opium (Opioid) Addiction – Pipeline by Benuvia Therapeutics Inc, 2022
Table 27: Opium (Opioid) Addiction – Pipeline by BioCorRx Inc, 2022
Table 28: Opium (Opioid) Addiction – Pipeline by BioXcel Therapeutics Inc, 2022
Table 29: Opium (Opioid) Addiction – Pipeline by Bridge Therapeutics Inc, 2022
Table 30: Opium (Opioid) Addiction – Pipeline by Bright Minds Biosciences Inc, 2022
Table 31: Opium (Opioid) Addiction – Pipeline by Camurus AB, 2022
Table 32: Opium (Opioid) Addiction – Pipeline by Ceruvia Lifesciences LLC, 2022
Table 33: Opium (Opioid) Addiction – Pipeline by Cessation Therapeutics LLC, 2022
Table 34: Opium (Opioid) Addiction – Pipeline by Copernicus Therapeutics Inc, 2022
Table 35: Opium (Opioid) Addiction – Pipeline by Creative Bio-Peptides Inc, 2022
Table 36: Opium (Opioid) Addiction – Pipeline by Delpor Inc, 2022
Table 37: Opium (Opioid) Addiction – Pipeline by DemeRx Inc, 2022
Table 38: Opium (Opioid) Addiction – Pipeline by DMK Pharmaceuticals Inc, 2022
Table 39: Opium (Opioid) Addiction – Pipeline by Elysium Therapeutics Inc, 2022
Table 40: Opium (Opioid) Addiction – Pipeline by Emergent BioSolutions Inc, 2022
Table 41: Opium (Opioid) Addiction – Pipeline by Ensysce Biosciences Inc, 2022
Table 42: Opium (Opioid) Addiction – Pipeline by Eolas Therapeutics Inc, 2022
Table 43: Opium (Opioid) Addiction – Pipeline by Epiodyne Inc, 2022
Table 44: Opium (Opioid) Addiction – Pipeline by Ethismos Research Inc, 2022
Table 45: Opium (Opioid) Addiction – Pipeline by Exxel Pharma Inc, 2022
Table 46: Opium (Opioid) Addiction – Pipeline by Fab’entech SA, 2022
Table 47: Opium (Opioid) Addiction – Pipeline by Fannin Partners LLC, 2022
Table 48: Opium (Opioid) Addiction – Pipeline by Gilgamesh Pharmaceuticals Inc, 2022
Table 49: Opium (Opioid) Addiction – Pipeline by Hunan Saiao Pharmaceutical Co Ltd, 2022
Table 50: Opium (Opioid) Addiction – Pipeline by Indivior Plc, 2022
Table 51: Opium (Opioid) Addiction – Pipeline by Inimmune Corp, 2022
Table 52: Opium (Opioid) Addiction – Pipeline by Jazz Pharmaceuticals Plc, 2022
Table 53: Opium (Opioid) Addiction – Pipeline by Kinoxis Therapeutics Pty Ltd, 2022
Table 54: Opium (Opioid) Addiction – Pipeline by Lyndra Therapeutics Inc., 2022
Table 55: Opium (Opioid) Addiction – Pipeline by Mayne Pharma Group Ltd, 2022
Table 56: Opium (Opioid) Addiction – Pipeline by Mebias Discovery LLC, 2022
Table 57: Opium (Opioid) Addiction – Pipeline by Mind Medicine MindMed Inc, 2022
Table 58: Opium (Opioid) Addiction – Pipeline by Nirsum Laboratories Inc, 2022
Table 59: Opium (Opioid) Addiction – Pipeline by Omeros Corp, 2022
Table 60: Opium (Opioid) Addiction – Pipeline by Opiant Pharmaceuticals Inc, 2022
Table 61: Opium (Opioid) Addiction – Pipeline by Orexo AB, 2022
Table 62: Opium (Opioid) Addiction – Pipeline by Orphomed Inc, 2022
Table 63: Opium (Opioid) Addiction – Pipeline by Osmotica Pharmaceutical Corp, 2022
Table 64: Opium (Opioid) Addiction – Pipeline by OYE Therapeutics Inc, 2022
Table 65: Opium (Opioid) Addiction – Pipeline by Palisades Therapeutics, 2022
Table 66: Opium (Opioid) Addiction – Pipeline by Phoenix PharmaLabs Inc, 2022
Table 67: Opium (Opioid) Addiction – Pipeline by Plumb Pharmaceuticals LLC, 2022
Table 68: Opium (Opioid) Addiction – Pipeline by Revive Therapeutics Ltd, 2022
Table 69: Opium (Opioid) Addiction – Pipeline by SafeRX Pharmaceuticals Inc, 2022
Table 70: Opium (Opioid) Addiction – Pipeline by Sen-Jam Pharmaceutical LLC, 2022
Table 71: Opium (Opioid) Addiction – Pipeline by Senzer Ltd, 2022
Table 72: Opium (Opioid) Addiction – Pipeline by Serina Therapeutics Inc, 2022
Table 73: Opium (Opioid) Addiction – Pipeline by Sparian Biosciences Inc, 2022
Table 74: Opium (Opioid) Addiction – Pipeline by Syntropharma Ltd, 2022
Table 75: Opium (Opioid) Addiction – Pipeline by Titan Pharmaceuticals Inc, 2022
Table 76: Opium (Opioid) Addiction – Pipeline by VDM Biochemicals Inc, 2022
Table 77: Opium (Opioid) Addiction – Pipeline by Vivreon Biosciences LLC, 2022
Table 78: Opium (Opioid) Addiction – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
Table 79: Opium (Opioid) Addiction – Pipeline by Zynerba Pharmaceuticals Inc, 2022
Table 80: Opium (Opioid) Addiction – Dormant Projects, 2022
Table 81: Opium (Opioid) Addiction – Dormant Projects, 2022 (Contd..1)
Table 82: Opium (Opioid) Addiction – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Opium (Opioid) Addiction, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings